BioUtah News
-
Fresenius Medical Care participates in three-way merger to create premier value-based kidney care provider in the U.S. – next important step in execution of growth strategy 2025
Fresenius Medical Care participates in three-way merger to create premier value-based kidney care provider in the U.S.
-
FACT SHEET: The Biden Administration’s Historic Investment in Pandemic Preparedness and Biodefense in the FY 2023 President’s Budget
The Biden Administration’s Investment in Pandemic Preparedness and Biodefense in the FY 2023 President’s Budget
-
Diversified Medical Healthcare Acquires Utah Lab, Dynasty Medical Laboratory Services
Diversified Medical Healthcare Acquires Utah Lab, Dynasty Medical Laboratory Services
-
Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes
Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes
-
Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors
Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors
-
PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update
SALT LAKE CITY, March 30, 2022 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue…
-
Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital
The total capital represents the largest seed financing for life science startups in Utah’s history
-
Halia Therapeutics Presented Data on Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer’s Disease
Halia Therapeutics presented data today on its NLRP3 inhibitor program at today’s 10th Annual Neurodegenerative Drug Development Summit.
-
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022
-
Pfizer’s $7B bet delivers phase 3 success, advancing bid to establish new drug in ulcerative colitis Arena
Pfizer’s $6.7 billion bet on Arena Pharmaceuticals has delivered a phase 3 success.
-
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Recursion reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021.
-
FierceBiotech recognizes Recursion as the #2 Biotech IPO of 2021!
FierceBiotech Special Report: The top 10 biotech IPOs of 2021
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
